


01-07-05

if w



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: AOKI et al.)	Examiner: Anish Gupta
)	
Serial Number: 10/726,904)	Art Unit: 1654
)	
Filed: December 2, 2003)	Confirmation No. 4172
)	
For: USE OF THE NEUROTOXIC)	
COMPONENT OF A BOTULINUM)	
TOXIN FOR TREATING VARIOUS)	
DISORDERS AND CONDITIONS)	
<u>AND ASSOCIATED PAIN</u>)	Irvine, California

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Applicant provides with regard to the patent application entitled USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING VARIOUS DISORDERS AND CONDITIONS AND ASSOCIATED PAIN, filed herewith one copy of a documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: January 5, 2005


Stephen Donovan
Registration Number 33,433


Please direct all inquiries and correspondence to:

Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date, **January 5, 2005**, in an envelope as "Express Mail Post Office to Addressee" Mailing Label number **EV295681593US** addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date: January 5, 2005

Adriane Giberson
Name of person mailing paper

Signature of person mailing paper

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 16952 CON1 CIP3	SERIAL NO.: 10/726,904
APPLICANT: Aoki et al.	TITLE: USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING VARIOUS DISORDERS AND CONDITIONS AND ASSOCIATED PAIN
FILING DATE: December 2, 2003	GROUP: 1654

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	2004/0014663	01/22/2004	Aoki et al.	514	12	06/12/2003
	AB	2004/0151740	08/05/2004	Aoki et al.	424	239.1	06/12/2003
	AC	2004/0126396	07/01/2004	Aoki et al.	424	239.1	05/21/2003
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	
	CB	
	CC	
	CD	
	CE	
	CF	
	CG	

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.